Moderna to Present at Upcoming Investor Conferences in June 2021

Rhea-AI Summary

Moderna (Nasdaq: MRNA) has announced its participation in two upcoming virtual investor conferences. The Jefferies Virtual Healthcare Conference will take place on June 3, 2021, at 10:00 a.m. ET, followed by the Goldman Sachs 42nd Annual Healthcare Conference on June 9, 2021, at 8:00 a.m. ET. Live webcasts of both events will be accessible on the Investors section of Moderna's website, and replays will be available for 30 days post-event. Moderna has evolved significantly in its 10-year history, establishing a strong clinical portfolio and a robust mRNA platform for various diseases.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in the following upcoming virtual investor conferences:

• Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:00 a.m. ET
• Goldman Sachs 42^nd Annual Healthcare Conference on Wednesday, June 9, 2021 at 8:00 a.m. ET

A live webcast of each presentation will be available under “Events and Presentations” in the Investors section of the Moderna website at https://investors.modernatx.com/. A replay of each webcast will be archived on Moderna’s website for 30 days following the presentation.

About Moderna

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most-effective vaccines against the COVID-19 pandemic.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Today, 24 development programs are underway across these therapeutic areas, with 14 programs having entered the clinic. Moderna has been named a top biopharmaceutical employer by Science for the past six years. To learn more, visit www.modernatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210528005032/en/

FAQ

What investor conferences is Moderna participating in regarding its stock MRNA?

Moderna is participating in the Jefferies Virtual Healthcare Conference on June 3, 2021, and the Goldman Sachs 42nd Annual Healthcare Conference on June 9, 2021.

When will Moderna present at the Jefferies Virtual Healthcare Conference?

Moderna will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 10:00 a.m. ET.

What time will Moderna's presentation be at the Goldman Sachs conference?

Moderna's presentation at the Goldman Sachs 42nd Annual Healthcare Conference will take place on June 9, 2021, at 8:00 a.m. ET.

Where can I watch Moderna's virtual conference presentations for stock MRNA?

You can watch Moderna's virtual conference presentations on the Investors section of their website, with replays available for 30 days after each event.

How has Moderna evolved in the past decade according to the recent PR?

Moderna has transformed from a research-stage company to a leader in mRNA therapeutics with a diverse clinical portfolio and significant manufacturing capabilities.